[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"sucrase-isomaltase-deficiency\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:sucrase-isomaltase-deficiency":63},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,49,76],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100616745","sucrase-isomaltase-si-genes-and-meal-load-100616745",false,"NCT07309601","Sucrase-Isomaltase (SI) Genes and Meal Load","Comparison of a Meal Load Between Normal and Functional Variants of the Sucrase-isomaltase (SI) Gene in IBS","SI IBS","Inclusion Criteria:\n\n* Diagnosis of irritable bowel syndrome (IBS)\n* Gene testing has been conducted regarding genes regulating the production of sucrase-isomaltase ensymes in previous dietary interventions using the starch- and sucrose reduced diet (SSRD) or multi-center study.\n\nExclusion Criteria:\n\n* Diagnosis of inflammatory bowel disease, celiac disease, bile salt malabsorption, gastroenteritis or enteric dysmotility\n* Severe food allergy\n* Serious heart-, lung-, cardiovascular-, malignant- or mental illness\n* Ongoing eating disorder\n* Pregnancy\n* Recent major gastrointestinal surgery\n* Alcohol and\u002For drug addiction","ALL","18 Years","70 Years",{"count":21,"type":22},70,"ESTIMATED","INTERVENTIONAL",[25],"NA","The goal of this interventional study is to examine whether those patients with irritable bowel syndrome (IBS) and a reduced abitility do degrade starch and sugar (lowe levels of enzymes) have lower raise in blood glucose after a meal than those with normal expression of enzymes. We also want to examine whether those IBS patients with reduced enzyme levels have increased bowel symptom in relation to this meal.\n\nThe main questions it aims to answer are:\n\nDoes reduced ability to degrade starch and sugar due to less enzyme activity lead to lower increase in blood glucose after a meal? Does reduced ability to degrade starch and sugar due to less enzyme activity lead to increased bowel symptoms after a meal?",[28,29],"IBS - Irritable Bowel Syndrome","Sucrase-Isomaltase Deficiency",[31,32,33,34,35],"IBS","SI genes","Starch and sucrose","blood glucose levels","bowel symptoms","RECRUITING","2026-04-28",{"date":39,"type":40},"2026-04-29","ACTUAL",{"date":42,"type":40},"2026-02-01",{"date":44,"type":22},"2030-02-01",{"name":46,"class":47},"Region Skane","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":57,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":58,"targetDuration":4,"studyType":60,"phases":4,"briefSummary":61,"conditions":62,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":48},"100575332","genetic-carbohydrate-maldigestion-as-model-to-study-food-hypersensitivity-mechanism-work-package-2-100575332","NCT06770907","Genetic Carbohydrate Maldigestion As Model to Study Food Hypersensitivity Mechanism (WORK PACKAGE 2)","Genetic Carbohydrate Maldigestion As a Model to Study Food Hypersensitivity Mechanism and Guide Personalised Treatment Using a Non-invasive Multiparametric Test (WORK PACKAGE 2)","GenMalCarb2","Inclusion Criteria for CSID subjects:\n\n* Aged ≥18 (all groups)\n* Subjects with genetically proven CSID\n* Previous negative endoscopy with biopsies excluding IBD or microscopic colitis in people above 50 years old.\n* Negative relevant additional screening (including exclusion of coeliac disease with TTG and IgA)\n* Ability to conform to the study protocol including the sucrose challenge.\n\nExclusion Criteria for CSID subjects:\n\n* Subjects on opioids and use of drugs known to alter GI motility for the duration of the study.\n* Presence of concurrent organic gastrointestinal disease (inflammatory bowel disease, coeliac disease, cancer), or a major disease such as diabetes, uncontrolled thyroid disease\n* Any history of bowel surgery (not appendectomy or cholecystectomy)\n* Contraindication to MRI scanning\n* Having taken part in another interventional research study within 3 months\n* Concurrent major confounding condition (e.g. alcohol or substance abuse in the last 2 years) based on the study clinician's judgement.\n\nInclusion Criteria for healthy participants:\n\n* Aged ≥18 years\n* Absence of Rome III IBS criteria\n* Non-SI variant confirmed (group 1) or Single-SI variants confirmed (group 2) or Double - SI variants confirmed (group 3)\n* Ability to conform to the study protocol including the sucrose challenge\n\nExclusion Criteria for healthy participants:\n\n* Person presenting with a functional or organic GI disorder.\n* Person presenting with underlying disease that may involve the GI tract (e.g. Parkinson's disease) or be associated with GI symptoms (e.g. anorexia nervosa, major depression).\n* Any history of bowel surgery (not appendectomy or cholecystectomy)\n* Contraindication to MRI scanning\n* Having taken part in another interventional research study within 3 months\n* Concurrent major confounding condition (e.g. alcohol or substance abuse in the last 2 years) based on the clinician's judgement.",true,{"count":59,"type":22},80,"OBSERVATIONAL","Irritable bowel syndrome (IBS) affects one in seven people with gastrointestinal (GI) symptoms that are detected without an established underlying organic cause. IBS strongly impacts quality of life, is a leading cause of work absenteeism, and consumes 0.5% of the healthcare annual budget. It manifests in women more than men with symptoms including abdominal pain, bloating, constipation (IBS-C), diarrhoea (IBS-D), and mixed presentations (IBS-M). The development of therapeutic options is hampered by the heterogeneity of IBS, the lack of specificity of its symptom-based definitions, and the poor understanding of the underlying pathophysiological mechanisms.\n\nMany people with IBS find that certain foods (particularly carbohydrates) trigger their symptoms and avoiding such foods has been shown to be effective in IBS. An example of such a diet is the low-FODMAP (fermentable oligo-, di-, monosaccharides and polyols) exclusion diet, developed by researchers at Monash University. This has suggested that the food-symptom relation may involve malabsorption of carbohydrates due to inefficient enzymatic breakdown of polysaccharides. However, only a percentage of subjects respond to this diet. Overall, the current findings relating to SI, suggest a strong potential for effective personalized therapeutic (dietary) interventions in subgroups of IBS subjects and suggest similar mechanisms should be investigated in relation to other genes involved in the digestion and absorption of carbohydrates (CDGs). This project aims to understand what the mechanisms for GI symptoms in subjects with these genetic alterations are. Aim of the study is to assess the gut response to a sucrose challenge in single-and double-carriers of the common hypomorphic sucrase-isomaltase variant p. (Val15Phe) vs non- carriers (negative controls) and CSID subjects (positive controls), applying an MRI multiparametric test combined with a breath test.",[63],"Sucrase Isomaltase Deficiency",[65],"sucrose isomaltase deficiency","NOT_YET_RECRUITING","2025-01-07",{"date":69,"type":40},"2025-01-13",{"date":71,"type":22},"2025-03",{"date":73,"type":22},"2026-03",{"name":75,"class":47},"University of Nottingham",{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":82,"enrollmentInfo":83,"targetDuration":4,"studyType":23,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100451485","sucrase-isomaltase-deficiency-as-a-cause-of-irritable-bowel-syndrome-100451485","NCT05159115","Sucrase-isomaltase Deficiency as a Cause of Irritable Bowel Syndrome","Validation of the 13C-labelled breath test to diagnose sucrase-isomaltase deficiency (n=40)\n\nInclusion Criteria:\n\n* Signed informed consent\n* BMI 18-30 kg\u002Fm2\n* Referred for gastroscopic examination with suspected GI disorder\n\nExclusion Criteria:\n\n• Unwilling or not capable of signing the informed consent\n\nSucrase-isomaltase deficiency as a cause of symptoms in patients with irritable bowel syndrome (n=80)\n\nInclusion Criteria:\n\n* Signed informed consent\n* BMI 18-30 kg\u002Fm2\n* IBS diagnosis according to Rome IV criteria\n\nExclusion Criteria:\n\n* Inflammatory bowel disease, celiac disease or diabetes mellitus\n* Chronic immune diseases affecting the GI-system\n* Unwilling\u002Funable to maintain a stable diet throughout the study period\n* Use of antibiotic treatment for the last 4 weeks\n* Currently on a restrictive diet","90 Years",{"count":59,"type":22},[25],"Irritable bowel syndrome (IBS) is a functional disorder causing troublesome symptoms and reduced quality of life. It affects 10-20% of the population, hence creates large costs for society. About 30-40% of all IBS patients do not benefit from current treatment options. Sucrase-isomaltase (SI) deficiency is an unexplored condition, that may explain symptoms in IBS patients who experience no effect from today's treatments. Currently, a duodenal biopsy is the gold standard for the diagnosis of SI deficiency, however the condition is not well investigated. A 13C-labelled breath test holds promise as a non-invasive alternative, but it has not previously been validated.\n\nThis project will address the knowledge gap related to a possible association between SI deficiency and IBS by addressing two research questions that have never been answered before. We aim to:\n\n1. Validate the 13C-labelled breath test as a diagnostic tool by assessing the strength of the association between the breath test and SI activity measured in duodenal biopsies\n2. Use the 13C-labelled breath test in a randomized dietary crossover trial comparing a starch and sucrose reduced diet (SSRD) with the standard low-FODMAP diet in IBS patients, to evaluate whether SI activity is associated with dietary changes according to symptom severity and gut microbiota composition",[87,88,89,63,90],"Irritable Bowel Syndrome","Sucrose Intolerance Due to Sucrase-Isomaltase Deficiency","Carbohydrate; Malabsorption","Functional Gastrointestinal Disorders","2022-01-18",{"date":93,"type":40},"2022-02-02",{"date":95,"type":22},"2022-03-14",{"date":97,"type":22},"2027-12-31",{"name":99,"class":47},"Lovisenberg Diakonale Hospital"]